Report Detail
Global (United States, European Union and China) Kidney Cancer Drugs Market Research Report 2019-2025
- RnM3715867 |
- 02 September, 2019 |
- Global |
- 145 Pages |
- QYResearch |
- Pharma & Healthcare
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
In 2019, the market size of Kidney Cancer Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Kidney Cancer Drugs.
This report studies the global market size of Kidney Cancer Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Kidney Cancer Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Market Segment by Product Type
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Market Segment by Application
Renal cell carcinoma (RCC)
Transitional cell carcinoma (TCC)
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Kidney Cancer Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Kidney Cancer Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Kidney Cancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Kidney Cancer Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Angiogenesis Inhibitors
- 1.3.3 mTOR Inhibitors
- 1.3.4 Monoclonal Antibodies
- 1.3.5 Cytokine Immunotherapy (IL-2)
- 1.4 Market Segment by Application
- 1.4.1 Global Kidney Cancer Drugs Market Share by Application (2019-2025)
- 1.4.2 Renal cell carcinoma (RCC)
- 1.4.3 Transitional cell carcinoma (TCC)
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Kidney Cancer Drugs Market Size
- 2.1.1 Global Kidney Cancer Drugs Revenue 2014-2025
- 2.1.2 Global Kidney Cancer Drugs Sales 2014-2025
- 2.2 Kidney Cancer Drugs Growth Rate by Regions
- 2.2.1 Global Kidney Cancer Drugs Sales by Regions 2014-2019
- 2.2.2 Global Kidney Cancer Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Kidney Cancer Drugs Sales by Manufacturers
- 3.1.1 Kidney Cancer Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Kidney Cancer Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Kidney Cancer Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Kidney Cancer Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Kidney Cancer Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Kidney Cancer Drugs Price by Manufacturers
- 3.4 Key Manufacturers Kidney Cancer Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Kidney Cancer Drugs Market
- 3.6 Key Manufacturers Kidney Cancer Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Angiogenesis Inhibitors Sales and Revenue (2014-2019)
- 4.1.2 mTOR Inhibitors Sales and Revenue (2014-2019)
- 4.1.3 Monoclonal Antibodies Sales and Revenue (2014-2019)
- 4.1.4 Cytokine Immunotherapy (IL-2) Sales and Revenue (2014-2019)
- 4.2 Global Kidney Cancer Drugs Sales Market Share by Type
- 4.3 Global Kidney Cancer Drugs Revenue Market Share by Type
- 4.4 Kidney Cancer Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Kidney Cancer Drugs Sales by Application
6 United States
- 6.1 United States Kidney Cancer Drugs Breakdown Data by Company
- 6.2 United States Kidney Cancer Drugs Breakdown Data by Type
- 6.3 United States Kidney Cancer Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Kidney Cancer Drugs Breakdown Data by Company
- 7.2 European Union Kidney Cancer Drugs Breakdown Data by Type
- 7.3 European Union Kidney Cancer Drugs Breakdown Data by Application
8 China
- 8.1 China Kidney Cancer Drugs Breakdown Data by Company
- 8.2 China Kidney Cancer Drugs Breakdown Data by Type
- 8.3 China Kidney Cancer Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Kidney Cancer Drugs Breakdown Data by Company
- 9.2 Rest of World Kidney Cancer Drugs Breakdown Data by Type
- 9.3 Rest of World Kidney Cancer Drugs Breakdown Data by Application
- 9.4 Rest of World Kidney Cancer Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Kidney Cancer Drugs Sales by Countries
- 9.4.2 Rest of World Kidney Cancer Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Bayer
- 10.1.1 Bayer Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.1.4 Kidney Cancer Drugs Product Introduction
- 10.1.5 Bayer Recent Development
- 10.2 Roche
- 10.2.1 Roche Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.2.4 Kidney Cancer Drugs Product Introduction
- 10.2.5 Roche Recent Development
- 10.3 GlaxoSmithKline
- 10.3.1 GlaxoSmithKline Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.3.4 Kidney Cancer Drugs Product Introduction
- 10.3.5 GlaxoSmithKline Recent Development
- 10.4 Novartis
- 10.4.1 Novartis Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.4.4 Kidney Cancer Drugs Product Introduction
- 10.4.5 Novartis Recent Development
- 10.5 Pfizer
- 10.5.1 Pfizer Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.5.4 Kidney Cancer Drugs Product Introduction
- 10.5.5 Pfizer Recent Development
- 10.6 Abbott Laboratories
- 10.6.1 Abbott Laboratories Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.6.4 Kidney Cancer Drugs Product Introduction
- 10.6.5 Abbott Laboratories Recent Development
- 10.7 Active Biotech
- 10.7.1 Active Biotech Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.7.4 Kidney Cancer Drugs Product Introduction
- 10.7.5 Active Biotech Recent Development
- 10.8 Amgen
- 10.8.1 Amgen Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.8.4 Kidney Cancer Drugs Product Introduction
- 10.8.5 Amgen Recent Development
- 10.9 Argos Therapeutics
- 10.9.1 Argos Therapeutics Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.9.4 Kidney Cancer Drugs Product Introduction
- 10.9.5 Argos Therapeutics Recent Development
- 10.10 ArQule
- 10.10.1 ArQule Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Kidney Cancer Drugs
- 10.10.4 Kidney Cancer Drugs Product Introduction
- 10.10.5 ArQule Recent Development
- 10.11 AVEO Pharmaceuticals
- 10.12 Bionomics
- 10.13 Bristol-Myers Squibb
- 10.14 Cerulean Pharma
- 10.15 Exelixis
- 10.16 Genentech
- 10.17 immatics biotechnologies
- 10.18 Immunicum
- 10.19 Ono Pharmaceutical
- 10.20 Onyx Therapeutics
- 10.21 Oxford BioMedica
- 10.22 Prometheus Laboratories
- 10.23 Seattle Genetics
- 10.24 Taiwan Liposome
- 10.25 Tracon Pharmaceuticals
- 10.26 Wilex
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Kidney Cancer Drugs Sales Channels
- 11.2.2 Kidney Cancer Drugs Distributors
- 11.3 Kidney Cancer Drugs Customers
12 Market Forecast
- 12.1 Global Kidney Cancer Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Kidney Cancer Drugs Sales Forecast by Type
- 12.3 Global Kidney Cancer Drugs Sales Forecast by Application
- 12.4 Kidney Cancer Drugs Forecast by Regions
- 12.4.1 Global Kidney Cancer Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Kidney Cancer Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Kidney Cancer Drugs. Industry analysis & Market Report on Kidney Cancer Drugs is a syndicated market report, published as Global (United States, European Union and China) Kidney Cancer Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Kidney Cancer Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
